Aurora Cannabis Inc. (ACB)

Nasdaq: ACB · Medicinal Chemicals & Botanical Products · Edmonton, AB · filing with the SEC since 2016

Full chart Alerts Compare

Grade6.3

◀ Past 7.1● Present 5.8▶ Future 6.1

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Aurora Cannabis Inc.

Nine metrics read from its own filings, by tense

Headline grade

6.3/10

◀ Past7.130% of the headline

● Present5.840% of the headline

▶ Future6.130% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

7.1/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.3/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 33% of this tense · 83rd percentile among 20 sector filers · read for itself

From the record

Aurora Cannabis Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

5.3/10

What has it actually done, year after year?

+31.1% a year over 7 filed years; profitable in 2 of 7.

weight 45% of this tense · 53rd percentile among 18 sector filers · read for its customers

From the record

Aurora Cannabis Inc.'s 7 filed years say what it did: revenue went from CAD 55 million in fiscal 2018 to CAD 343 million in fiscal 2025, up 31.1% a year; it rose in 4 of 6 years; the deepest fall was 18% from fiscal 2020 to fiscal 2022; net income was positive in 2 of 7 of those years (its annual reports).

What it rests on

revenue growth over the filed span31.1%top 31% of its family
the share of years revenue rosebottom 44% of its family
the share of filed years with a profittop 47% of its family
the deepest fall from a revenue peak17.6%bottom 47% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

9.2/10

How has it treated the people who own it?

SI estimate 9.2/10, confidence 35 of 100 (one part).

weight 22% of this tense · 92nd percentile among 18 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 8% of 18 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 18 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Aurora Cannabis Inc.'s shareholder treatment is put at 9.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 8% of 18 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

5.8/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

5.5/10

Is it financially healthy right now?

ROE 0%: 0¢ of profit per shareholder dollar. Leverage 29%: owes 29¢ per asset dollar.

weight 45% of this tense · 55th percentile among 20 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-03-31, Aurora Cannabis Inc. earned about 0 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 22 cents per dollar of everything the company owns. Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count grew 26.9% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 32% of its family
return on equitytop 22% of its family
gross profit against assetstop 50% of its family
the share count against the year beforebottom 25% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

6.7/10

How strong is its position in its industry?

top 33% of 18 in its family; net margin 0.5%.

weight 33% of this tense · 67th percentile among 18 sector filers · read for its customers

From the record

Aurora Cannabis Inc.'s standing among 18 graded names in its industry family: revenue of CAD 343 million in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of 0.5% ranks in the top 25%; revenue growth of 9.4% a year over the last 3 filed years ranks in the top 42% (its annual reports).

What it rests on

net margin0.5%top 25% of its family
three-year revenue growth9.4%top 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 12 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 12 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned: family median, 12 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Aurora Cannabis Inc.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 12 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.1/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

5.6/10

How much room does it have to grow?

top 44% of 18 in its family for room to expand.

weight 45% of this tense · 56th percentile among 18 sector filers · read for itself

From the record

Aurora Cannabis Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of CAD 138 million against debt of CAD 42 million leaves 11.2% of its assets as net cash, top 50% of its family; cash from operations less capital spending is 4.7% of revenue (top 36%); a gross margin of 54.6% (top 32%); research spending of 1.1% of revenue (bottom 41%) (its annual report).

What it rests on

cash less debt against assets11.2%top 50% of its family
cash from operations less capital spending against revenue4.7%top 36% of its family
gross margin54.6%top 32% of its family
research spending against revenue1.1%bottom 41% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

4.9/10

What could actually drive growth from here?

bottom 49% of 18 in its family for growth drivers.

weight 33% of this tense · 49th percentile among 18 sector filers · read for its customers

From the record

Aurora Cannabis Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 9.4% a year over the last three filed years against 31.1% over all 7, slowing (bottom 47% of its family); the newest year grew 27.3% (top 14%); research spending grew -26.1% a year (bottom 38%); capital spending grew -30.4% a year (bottom 26%) (its annual reports). Aurora Cannabis Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-21.7 points a yearbottom 47% of its family
the newest year's revenue growth27.3%top 14% of its family
three-year growth of research spending-26.1%bottom 38% of its family
three-year growth of capital spending-30.4%bottom 26% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

9.0/10

Did its newest year beat what its own record pointed to?

top 10% of 18 in its family for expectations against reality.

weight 22% of this tense · 90th percentile among 18 sector filers · read for its shareholders

From the record

Aurora Cannabis Inc.'s newest year against its own record: revenue of CAD 343 million in fiscal 2025 came in 23% above the CAD 279 million its prior three years' pace pointed to (top 3% of its family); net income of CAD 2 million against a prior three-year average of CAD 827 million (top 14%); a net margin of 0.5% against losses larger than its revenue before (top 14%) (its annual reports).

What it rests on

revenue against the prior three years' pace23.0%top 3% of its family
net income against the prior three years' average+100%top 14% of its family
net margin against its prior averageup more than 100 pointstop 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ACB · research, not advice